These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19178029)

  • 1. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin).
    Machado V; Cabral A; Monteiro P; Gonçalves L; Providência LA
    Rev Port Cardiol; 2008 Oct; 27(10):1277-96. PubMed ID: 19178029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart.
    de Nigris F; Rienzo M; Schiano C; Fiorito C; Casamassimi A; Napoli C
    Eur J Cancer; 2008 Feb; 44(3):334-40. PubMed ID: 18194856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
    Kalay N; Basar E; Ozdogru I; Er O; Cetinkaya Y; Dogan A; Inanc T; Oguzhan A; Eryol NK; Topsakal R; Ergin A
    J Am Coll Cardiol; 2006 Dec; 48(11):2258-62. PubMed ID: 17161256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity.
    Oliveira PJ; Bjork JA; Santos MS; Leino RL; Froberg MK; Moreno AJ; Wallace KB
    Toxicol Appl Pharmacol; 2004 Oct; 200(2):159-68. PubMed ID: 15476868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial.
    Tashakori Beheshti A; Mostafavi Toroghi H; Hosseini G; Zarifian A; Homaei Shandiz F; Fazlinezhad A
    Cardiology; 2016; 134(1):47-53. PubMed ID: 26866364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carvedilol: just another Beta-blocker or a powerful cardioprotector?
    Carreira RS; Monteiro P; Gon Alves LM; Providência LA
    Cardiovasc Hematol Disord Drug Targets; 2006 Dec; 6(4):257-66. PubMed ID: 17378771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-gingerol ameliorated doxorubicin-induced cardiotoxicity: role of nuclear factor kappa B and protein glycation.
    El-Bakly WM; Louka ML; El-Halawany AM; Schaalan MF
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):833-41. PubMed ID: 23014738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin-induced cardiomyopathy treated with carvedilol.
    Fazio S; Palmieri EA; Ferravante B; Bonè F; Biondi B; Saccà L
    Clin Cardiol; 1998 Oct; 21(10):777-9. PubMed ID: 9789703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.
    Spallarossa P; Garibaldi S; Altieri P; Fabbi P; Manca V; Nasti S; Rossettin P; Ghigliotti G; Ballestrero A; Patrone F; Barsotti A; Brunelli C
    J Mol Cell Cardiol; 2004 Oct; 37(4):837-46. PubMed ID: 15380674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity.
    Ludke AR; Al-Shudiefat AA; Dhingra S; Jassal DS; Singal PK
    Can J Physiol Pharmacol; 2009 Oct; 87(10):756-63. PubMed ID: 19898559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats.
    Arozal W; Watanabe K; Veeraveedu PT; Ma M; Thandavarayan RA; Sukumaran V; Suzuki K; Kodama M; Aizawa Y
    Toxicology; 2010; 274(1-3):18-26. PubMed ID: 20452391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
    Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
    Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol.
    Pereira GC; Silva AM; Diogo CV; Carvalho FS; Monteiro P; Oliveira PJ
    Curr Pharm Des; 2011; 17(20):2113-29. PubMed ID: 21718248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
    Santos DL; Moreno AJ; Leino RL; Froberg MK; Wallace KB
    Toxicol Appl Pharmacol; 2002 Dec; 185(3):218-27. PubMed ID: 12498738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carvedilol: therapeutic application and practice guidelines.
    Bleske BE; Gilbert EM; Munger MA
    Pharmacotherapy; 1998; 18(4):729-37. PubMed ID: 9692647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
    Harake D; Franco VI; Henkel JM; Miller TL; Lipshultz SE
    Future Cardiol; 2012 Jul; 8(4):647-70. PubMed ID: 22871201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
    Theodoulou M; Hudis C
    Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carvedilol protects ischemic cardiac mitochondria by preventing oxidative stress.
    Carreira R; Duarte A; Monteiro P; Santos MS; Rego AC; Oliveira CR; Gonçalves LM; Providência LA
    Rev Port Cardiol; 2004 Nov; 23(11):1447-55. PubMed ID: 15693697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.